Trial Profile

Safety and Efficacy Study of Oncolytic Virus Intratumoral Injection in Combination With HX-008 Intravenous Injection and Radiotherapy for Liver Metastasis in Melanoma Patients With Liver Metastasis Who Lack or Become Refractory to Standard Treatment

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jun 2023 Status changed from not yet recruiting to recruiting according to result presented at the 59th Annual Meeting of the American Society of Clinical Oncology
06 Jun 2023 Results (n=10) assessing assess the safety and efficacy of OH2 and pucotenlimab (a humanized immunoglobulin G4 monoclonal antibody) combine with liver metastasis radiation in melanoma pts presented at the 59th Annual Meeting of the American Society of Clinical Oncology
11 Oct 2021 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com